NovaBridge to Host Call for Phase 2a Wet AMD Data Review of VIS-101
NBP has more than doubled off its 52-week low of $0.595.
Summary
NovaBridge Biosciences announced it will host a virtual business update call on March 9, 2026, to review Phase 2a clinical data for VIS-101 in wet age-related macular degeneration (wet AMD).
Key Events · Product Development and Regulatory · NBP
-
Phase 2a Data Review Call Scheduled
NovaBridge Biosciences will host a virtual business update call on Monday, March 9, 2026, to review Phase 2a clinical data for VIS-101 in wet age-related macular degeneration (wet AMD).
-
Key Drug Candidate VIS-101
VIS-101 is a bispecific, tetravalent dual VEGF-A/ANG-2 inhibitor, designed for more potent and durable treatment benefits in wet AMD, diabetic macular edema (DME), and retinal vein occlusion (RVO).
-
Majority Ownership in Visara
NovaBridge is the majority shareholder of Visara, Inc., which holds global development and commercialization rights to VIS-101 outside of Greater China and certain other Asian territories.
-
Anticipated Best-in-Class Potential
The company highlights VIS-101's potential to be a best-in-class treatment, offering more effective and durable results than current standard of care for wet AMD patients.
Analysis · NBP · Life Sciences
NovaBridge Biosciences has scheduled a business update call to review Phase 2a clinical data for VIS-101, a key drug candidate for wet age-related macular degeneration (wet AMD). This announcement signals an imminent and significant data disclosure for a pipeline asset that the company believes has 'best-in-class' potential. Investors should monitor the March 9th call for the actual data presentation, as Phase 2a results are crucial for determining the drug's efficacy and safety and its path forward in clinical development.
At the time of this filing, NBP was trading at $3.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $397.8M. The 52-week trading range was $0.60 to $6.79. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.